A detailed history of Panagora Asset Management Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Panagora Asset Management Inc holds 11,639 shares of EXEL stock, worth $405,386. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,639
Previous 11,781 1.21%
Holding current value
$405,386
Previous $264,000 14.39%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$21.96 - $27.6 $3,118 - $3,919
-142 Reduced 1.21%
11,639 $302,000
Q2 2024

Jul 29, 2024

SELL
$20.34 - $23.73 $305,872 - $356,851
-15,038 Reduced 56.07%
11,781 $264,000
Q1 2024

May 07, 2024

SELL
$20.17 - $23.93 $216,040 - $256,314
-10,711 Reduced 28.54%
26,819 $636,000
Q4 2023

Feb 08, 2024

SELL
$19.25 - $24.13 $724,493 - $908,156
-37,636 Reduced 50.07%
37,530 $900,000
Q3 2023

Oct 31, 2023

BUY
$19.04 - $22.74 $1.05 Million - $1.26 Million
55,193 Added 276.34%
75,166 $1.64 Million
Q2 2023

Aug 11, 2023

SELL
$18.17 - $20.48 $3.98 Million - $4.49 Million
-219,194 Reduced 91.65%
19,973 $381,000
Q1 2023

May 11, 2023

BUY
$16.3 - $19.41 $3.57 Million - $4.26 Million
219,275 Added 1102.33%
239,167 $4.64 Million
Q4 2022

Feb 13, 2023

BUY
$14.96 - $17.39 $9,903 - $11,512
662 Added 3.44%
19,892 $319,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $1,536 - $2,182
98 Added 0.51%
19,230 $302,000
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $333,662 - $443,097
19,132 New
19,132 $398,000
Q4 2021

Feb 10, 2022

SELL
$15.84 - $21.88 $835,433 - $1.15 Million
-52,742 Closed
0 $0
Q3 2021

Nov 10, 2021

SELL
$16.3 - $21.14 $92,323 - $119,736
-5,664 Reduced 9.7%
52,742 $1.12 Million
Q2 2021

Aug 11, 2021

BUY
$17.95 - $25.56 $6,426 - $9,150
358 Added 0.62%
58,406 $1.06 Million
Q1 2021

May 12, 2021

SELL
$20.53 - $25.22 $1.55 Million - $1.9 Million
-75,526 Reduced 56.54%
58,048 $1.31 Million
Q4 2020

Feb 10, 2021

SELL
$18.39 - $24.8 $1.97 Million - $2.66 Million
-107,238 Reduced 44.53%
133,574 $2.68 Million
Q3 2020

Nov 13, 2020

BUY
$20.67 - $26.94 $4.83 Million - $6.29 Million
233,484 Added 3186.19%
240,812 $5.89 Million
Q2 2020

Aug 12, 2020

SELL
$16.46 - $27.42 $2,847 - $4,743
-173 Reduced 2.31%
7,328 $174,000
Q1 2020

May 14, 2020

BUY
$14.46 - $21.8 $636 - $959
44 Added 0.59%
7,501 $129,000
Q4 2019

Feb 12, 2020

BUY
$15.15 - $18.89 $16,649 - $20,760
1,099 Added 17.29%
7,457 $131,000
Q3 2019

Nov 12, 2019

BUY
$17.68 - $22.65 $495 - $634
28 Added 0.44%
6,358 $112,000
Q4 2018

Feb 14, 2019

BUY
$13.65 - $21.8 $84,220 - $134,506
6,170 Added 3856.25%
6,330 $125,000
Q3 2018

Nov 13, 2018

SELL
$15.87 - $22.4 $412 - $582
-26 Reduced 13.98%
160 $3,000
Q2 2018

Aug 14, 2018

SELL
$18.56 - $22.45 $171,234 - $207,123
-9,226 Reduced 98.02%
186 $4,000
Q1 2018

May 15, 2018

BUY
$22.15 - $31.89 $62,485 - $89,961
2,821 Added 42.8%
9,412 $208,000
Q4 2017

Feb 14, 2018

BUY
$24.23 - $30.93 $155,193 - $198,106
6,405 Added 3443.55%
6,591 $200,000
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $4,343 - $5,438
186
186 $5,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.